Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Dashboard
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
Membership Levels
By The Numbers
Formulation
80 Articles Available
1
4
Can't find what you're looking for? Try our
advanced search
.
License Agreement
SeraNovo Enters into License Agreement with Carna Biosciences for Development of Oral Formulation of Carna's Kinase Inhibitor
PR-M10-19-NI-046
Semisolid Dosage Forms
Supporting Commercial Manufacturing of Semisolid Dosage Forms
PAP-Q3-19-CL-034
Drug Development
Looking Beyond Current Treatments for CNS Diseases and Disorders
PAP-Q3-19-CL-036
Thermal Stability
Stabilizing and Protecting Biologic Formulations
PAP-Q3-19-CL-017
Commercialization
Supporting Commercialization with Specialized Technologies
PAP-Q2-2019-CL-034
Formulation
Taking Extra Care with Formulation
PAP-Q2-2019-CL-016
Formulation
Developing and Characterizing DPI Formulations for Biologics
PAP-Q1-2019-CL-002
Virtual Panel
Reprioritizing to Bring FY2020 into Focus
PAP-Q1-2019-CL-032
The Ideal Capsule Supplier: Using A Holistic Approach to Facilitate Customer Success
Formulation
The Coming of Age of Amorphous Solid Dispersions
PAP-Q4-18-CL-004
Influenza
FluMist Shipped by AstraZeneca
PAO-M10-18-NI-007
Collaboration
Context Therapeutics Signs Strategic Research Collaborations for Apristor® (onapristone extended release) With Key Academic Leaders in the Progesterone Receptor (PR) and Breast Cancer Fields
PR-M08-18-NI-086
Building a Robust Supply Chain with Dependable Quality Primary Suppliers
PAO-M07-18-CL-001
Clinical Data
Pulmatrix Announces Positive Top-Line Preliminary Results from Part 3 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole
PR-M07-18-NI-058
Equipment Selection
Tackling Powder Flow Problems by Choosing the Right Equipment
PAO-05-18-CL-007
OSD Facility Design
Modern OSD Facility Design Considerations for Operational Efficiency and Regulatory Compliance
PAP-Q2-18-CL-012
Controlled Nucleation
Achieving Controlled Nucleation During Aseptic Lyophilization
PAP-Q2-18-CL-018
Formulation
Differentiating Generic SODFs with Hard Capsule Formulations
PAO-Q1-18-CL-004
Collaboration
Xeris Pharmaceuticals Announces a Formulation Development Collaboration with Asahi Kasei Pharma
PR-M03-18-NI-061
Capsules
Overcoming Formulation Challenges with Liquid-fill Capsules
PAP-Q1-18-CL-004
Formulation
Investing in New Technologies for Innovative Functional Solutions
PAP-Q1-18-CL-009
Opadry System
Colorcon, Inc. Transforms the Sugar Coating Process with a New Opadry System
PR-M01-18-NI-071
Launch
DSM Sinochem Pharmaceuticals successfully launches Rosuvastatin finished dosage formulation in Western Europe
PR-M01-18-NI-054
Innovation
Single-Pill, HIV-1 Combination Therapy Approved
PAO-M11-17-NI-050
1
4
»
